Corbus Pharmaceuticals I... (CRBP)
Corbus Pharmaceuticals Statistics
Share Statistics
Corbus Pharmaceuticals has 12.23M shares outstanding. The number of shares has increased by 14.46% in one year.
Shares Outstanding | 12.23M |
Shares Change (YoY) | 14.46% |
Shares Change (QoQ) | 0.43% |
Owned by Institutions (%) | 0% |
Shares Floating | 10.55M |
Failed to Deliver (FTD) Shares | 1.29K |
FTD / Avg. Volume | 0.54% |
Short Selling Information
The latest short interest is 2.4M, so 19.68% of the outstanding shares have been sold short.
Short Interest | 2.4M |
Short % of Shares Out | 19.68% |
Short % of Float | 22.01% |
Short Ratio (days to cover) | 8.99 |
Valuation Ratios
The PE ratio is -3.2 and the forward PE ratio is -1.73. Corbus Pharmaceuticals's PEG ratio is 0.05.
PE Ratio | -3.2 |
Forward PE | -1.73 |
PS Ratio | 0 |
Forward PS | 0.4 |
PB Ratio | 0.9 |
P/FCF Ratio | -3.08 |
PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Corbus Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.94, with a Debt / Equity ratio of 0.02.
Current Ratio | 12.94 |
Quick Ratio | 12.94 |
Debt / Equity | 0.02 |
Debt / EBITDA | - |
Debt / FCF | -0.08 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.44M |
Employee Count | 28 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.49% in the last 52 weeks. The beta is 2.63, so Corbus Pharmaceuticals's price volatility has been higher than the market average.
Beta | 2.63 |
52-Week Price Change | -86.49% |
50-Day Moving Average | 7.86 |
200-Day Moving Average | 26.66 |
Relative Strength Index (RSI) | 28.93 |
Average Volume (20 Days) | 239.73K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | 0 |
Net Income | -40.21M |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -3.68 |
Balance Sheet
The company has 17.2M in cash and 3.24M in debt, giving a net cash position of 13.96M.
Cash & Cash Equivalents | 17.2M |
Total Debt | 3.24M |
Net Cash | 13.96M |
Retained Earnings | -476.89M |
Total Assets | 155.88M |
Working Capital | 141.16M |
Cash Flow
In the last 12 months, operating cash flow was -41.79M and capital expenditures 0, giving a free cash flow of -41.79M.
Operating Cash Flow | -41.79M |
Capital Expenditures | 0 |
Free Cash Flow | -41.79M |
FCF Per Share | -3.83 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CRBP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CRBP is $52, which is 900% higher than the current price. The consensus rating is "Buy".
Price Target | $52 |
Price Target Difference | 900% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Stock Splits
The last stock split was on Feb 14, 2023. It was a backward split with a ratio of 1:30.
Last Split Date | Feb 14, 2023 |
Split Type | backward |
Split Ratio | 1:30 |
Scores
Altman Z-Score | -1.34 |
Piotroski F-Score | 1 |